Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Gabapentin industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Type trends
2.1.4 Dosage form trends
2.1.5 Application trends
2.1.6 Distribution channel trends
Chapter 3 Gabapentin Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidences of neuropathic pain
3.2.1.2 Increasing off-label use of gabapentin
3.2.1.3 Expanded indications of gabapentin
3.2.1.4 Rising awareness of gabapentin as an effective treatment option for pain management
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with gabapentin
3.2.2.2 Availability of alternative treatments
3.2.2.3 Increasing misuse of gabapentin
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By dosage form
3.3.3 By application
3.3.4 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 Gabapentin Market Estimates and Forecast, By Type, 2018-2032 (USD Million)
5.1 Key trends, by type
5.2 Generic
5.3 Branded
Chapter 6 Gabapentin Market Estimates and Forecast, By Dosage Form, 2018-2032 (USD Million)
6.1 Key trends, by dosage form
6.2 Capsule
6.3 Tablet
6.4 Oral solution
Chapter 7 Gabapentin Market Estimates and Forecast, By Application, 2018-2032 (USD Million)
7.1 Key trends, by application
7.2 Epilepsy
7.3 Neuropathic pain
7.4 Restless legs syndrome
7.5 Other applications
Chapter 8 Gabapentin Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Gabapentin Market Estimates and Forecast, By Region, 2018-2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Pfizer Inc.
10.2 Glenmark Pharmaceuticals Limited`
10.3 Sun Pharmaceutical Industries Ltd.
10.4 Ascend Laboratories, LLC
10.5 Apotex Inc.
10.6 Teva Pharmaceutical Industries Ltd.
10.7 Aurobindo Pharma Ltd.
10.8 Amneal Pharmaceuticals LLC
10.9 Cipla Inc.
10.10 BP Pharmaceuticals Laboratories Company
10.11 Assertio Holdings, Inc.
10.12 Arbor Pharmaceuticals, Inc.
10.13 Zydus Pharmaceuticals, Inc
10.14 Dr. Reddy's Laboratories Ltd.
